Brief Summary

The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

1,260

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Aug 2026

Geographic Reach

6 countries

6 active sites

Status

completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

3 days study duration

Study Start

First participant enrolled

August 28, 2026

Completed

3 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2026

Completed

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2026

Completed

23 days until next milestone

First Submitted

Initial submission to the registry

September 23, 2026

Completed

7 days until next milestone

First Posted

Study publicly available on registry

September 30, 2026

Completed

Last Updated

September 30, 2026

Status Verified

September 1, 2026

Enrollment Period

3 days

First QC Date

September 23, 2026

Last Update Submit

September 23, 2026

Conditions

Overweight Obesity

Outcome Measures

Primary Outcomes (12)

Change in Food Noise Questionnaire (FNQ) score
Food noise assessed retrospectively prior to Wegovy initiation and at data capture using the Food Noise Questionnaire (FNQ). The questionnaire evaluates intrusive and persistent food-related thoughts. Each item is scored 0-5, with a total score range of 0-20. Higher scores indicate greater food noise
At data capture (Day 1)
Change in Body Weight
Change in body weight (kg) from initiation of Wegovy to data capture. Weight measured prior to Wegovy initiation and at data collection.
At data capture (Day 1)
Health-Related Quality of Life Measured by EQ-5D-5L
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The EQ-5D-5L consists of 5 items rated on a 5-point Likert scale that ranges from 1 (no problems) to 5 (extreme problems). Higher index scores indicate better health-related quality of life.
At data capture (Day 1)
Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)
Participant-rated overall health status measured using the EQ-VAS. Scores range from 0 to 100, where higher scores indicate better perceived health.
At data capture (Day 1)
Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)
Participant-reported adherence to Wegovy treatment assessed using the Adelphi Adherence Questionnaire (ADAQ). The overall adherence summary score ranges from 0 to 4, with lower scores indicating greater medication adherence.
At data capture (Day 1)
Number of Participant Satisfaction With Wegovy
Participant satisfaction with Wegovy treatment assessed as less than satisfied, satisfied, or more than satisfied according to perceived treatment performance relative to expectations.
At data capture (Day 1)
Change in Body Mass Index (BMI)
Change in body mass index (kg/m²) from Wegovy initiation to data capture will be reported
At data capture (Day 1)
Percent Change in Body Weight
Percentage change in body weight between Wegovy initiation and data capture will be reported.
At data capture (Day 1)
Number of Participants with Achievement of Weight-Loss Target
Participant-reported achievement of the predefined weight-loss goal (Yes/No). Participants may be classified as having reached or exceeded their target weight loss.
At data capture (Day 1)
Number of Participants who Concern About Future Weight Gain
Number of Participant concern regarding regaining weight after discontinuation of Wegovy treatment will be reported.
At data capture (Day 1)
Impact of Wegovy on Weight-Related Burden
Degree to which participants were bothered by their weight before starting Wegovy and at data capture after receiving Wegovy.
At data capture (Day 1)
Impact of Wegovy on Daily Life and Health Behaviours
Changes in work-life impact, cigarette smoking, shisha smoking, and alcohol consumption since initiation of Wegovy.
At data capture (Day 1)

Study Arms (1)

Obesity PLUS I disease specific programme (DSP)

Patients included in this study were those who had been diagnosed with overweight or obesity and had been initiated on Wegovy (semaglutide) at least 16 weeks prior to the date the DSP survey was conducted. This study is based on a retrospective analysis of existing physician-reported data collected through the DSP survey.

Drug: Semaglutide

Interventions

SemaglutideDRUG

This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Obesity PLUS I disease specific programme (DSP)

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Participants receiving semaglutide for at least 16 weeks are included for secondary database analysis.

You may qualify if:

Aged 18 years or older
Currently receiving Wegovy for at least 16 weeks, who at initiation of Wegovy had either: BMI of more than or equal to (≥) 27 to less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity and BMI of ≥30 kg/m\^2
Not currently involved in a clinical trial for overweight or obesity

You may not qualify if:

\- This is a secondary database analysis

Contact the study team to confirm eligibility.